Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome.

Abstract

Recently heart failure with preserved ejection fraction (HFpEF) has emerged as a huge epidemic. Increasing evidence shows the role of energy deficiency in the pathophysiology of HFpEF. In the current study, we hypothesize that the use of metabolic modulator perhexiline would correct myocardial energy deficiency and improve exercise capacity and diastolic abnormalities in patients with this syndrome.

• Authors: Satnam Singh, Roger Beadle, Donnie Cameron, Amelia Rudd, Maggie Bruce, Baljit Jagpal, Konstantin Schwarz, Gemma Brindley, Fergus Mckiddie, Peter Nightingale, Chim Lang, Dana Dawson, Michael Frenneaux
• Journal: Future cardiology (Future Cardiol) Vol. 10 Issue 6 Pg. 693-8 (Nov 2014) ISSN: 1744-8298 [Electronic] England
• PMID: 25495811 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Cardiovascular Agents
• Perhexiline

Topics

• Cardiovascular Agents (therapeutic use)
• Clinical Protocols
• Double-Blind Method
• Heart Failure (drug therapy, physiopathology)
• Humans
• Outcome Assessment, Health Care
• Perhexiline (therapeutic use)
• Stroke Volume (physiology)
• Syndrome